Market Cap 7.50B
Revenue (ttm) 3.03B
Net Income (ttm) -1.43B
EPS (ttm) N/A
PE Ratio 5.15
Forward PE 7.24
Profit Margin -47.23%
Debt to Equity Ratio 0.65
Volume 4,112,700
Avg Vol 2,567,858
Day's Range N/A - N/A
Shares Out 173.30M
Stochastic %K 23%
Beta 1.33
Analysts Sell
Price Target $58.71

Company Profile

Alexandria Real Estate Equities, Inc. an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Mega campus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland,...

Industry: REIT - Office
Sector: Real Estate
Phone: 626 578 0777
Fax: 626 578 0896
Website: www.are.com
Address:
26 North Euclid Avenue, Pasadena, United States
Hopipaytrader
Hopipaytrader Apr. 2 at 8:34 PM
$ARE rate cuts, move to risk on in biotech already started, expect filled lab spaces, good outlook
0 · Reply
StockFactz
StockFactz Apr. 2 at 7:20 PM
$ARE An overcriticized move is also that people dislike ARE creating rent concessions for the short term to entice new leasees or to encourage renewals. If they are able to fill in space with rent concessions that is infinitely better for the company than the current bear projections. Q4 2025 was actually a huge leasing quarter for them, it was double that of the last 5 quarters. For example right now the stock is priced as if the occupancy rate will drop to 3% this year. If they can backfill the space or encourage renewals with a 20% discount then the company is actually only losing 0.6%. This is a short term strategy that will help the company while the market adjusts and gives time for tenants to rotate back in with biotech cycle. The bear thesis is that this is indicative of a long term spiral and bleed out period, but it seems to be this is an obvious and responsible play by the company to open up their options and increase cash flow https://www.costar.com/article/431378465/alexandrias-leasing-jump-signals-potential-rebound-in-biotech-property-demand
0 · Reply
StockFactz
StockFactz Apr. 2 at 7:05 PM
$ARE The current price levels only make sense if the reality is continued bleed out or drop in tenancy across the next 5-10 years and occupancy dips to like 60%. Which doesn't really seem to be rooted in any factuality. It seems to me like theres a fairly decent chance things will turn bullish or even remain neutral at the very least. BIG HYPOTHETICAL, but if occupancy recovers to 95% in the next 2 years (which is just a 6% or so gain), then the consensus is that this stock is worth double or triple. I haven't seen any compelling evidence that the bearish case is any more likely than a bullish or neutral case. In fact I would estimate that a dip to 60% tenancy is practically less than 5%. A lighter bear case of 80% tenancy is maybe 15%. Neutral case is 45%, bullish case is 35%.
1 · Reply
StockFactz
StockFactz Apr. 2 at 6:44 PM
$ARE Nice little snippet!!! Quality innovation centers are always going to be needed, and perhaps even more so in the coming years. The current narrative that AI will reduce the need for lab space seems completely backwards. Buy and hold for 5 years! This will be at $200 levels and the dividend will be 2-4X.
0 · Reply
weko
weko Apr. 2 at 1:01 PM
$ARE Just saw 45% dividend cut
1 · Reply
weko
weko Apr. 2 at 12:05 PM
$ARE The trend line on the monthly chart hits at long term 2010-2014 support around 39-40. I will buy back in if it hits there with a dividend near 10 pc
2 · Reply
Daniel3303
Daniel3303 Apr. 2 at 11:57 AM
$ARE https://www.cushmanwakefield.com/en/insights/life-science-report
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 10:53 PM
$ARE The market hates logical analysis but I’m gonna provide some anyways. First off it’s no secret that different REITs will a command significantly different valuations and it is often difficult to compare two directly. However let’s work with a key assumption that $BXP AND $ARE both have some key similarities. Namely 1. They both provide premium office real estate in premium US hubs. (ARE does only lab space) 2. They are both industry leaders 3. They are both facing potential headwinds from occupancy and supply Now let’s consider the indisputable facts that $ARE has significantly stickier tenants and a much stronger moat in its respective industry. Let’s also consider that $ARE’s occupancy rate is currently 4% higher, and their debt to equity ratio is extremely trim compared to BXPs high leverage and weaker cash position. Lets also consider that lab space is a lot more “necessary” than traditional office space in the sense that wet labs are in person research is a requirement
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 10:13 PM
$ARE scratch that, the P/FFO is actually 6.7X after today. If it doubled in price it would be at the low end of its historical average of around 14X. Occupancy is at 90%, a majority of the biggest blue chip leases don’t expire dor 7+ years.
0 · Reply
Arb_raccoon
Arb_raccoon Apr. 1 at 8:55 PM
$ARE Entering here - see you boys at $200
0 · Reply
Latest News on ARE
Conflict Without Closure

Mar 29, 2026, 9:00 AM EDT - 5 days ago

Conflict Without Closure

AGG AGNC AGNCM AGNCN AGNCO AGNCP AHRT


5 ‘Healthy' Dividends Paying Up To 14.1%

Mar 22, 2026, 9:45 AM EDT - 12 days ago

5 ‘Healthy' Dividends Paying Up To 14.1%

BME DOC HQH PFE


What Active REIT Managers Bought And Sold In Q4 2025

Mar 21, 2026, 7:15 AM EDT - 13 days ago

What Active REIT Managers Bought And Sold In Q4 2025

ADC AHR AMH AVB CCI CNS CPT


Alexandria Real Estate: A Long-Term Approach Is Required

Mar 16, 2026, 8:00 AM EDT - 18 days ago

Alexandria Real Estate: A Long-Term Approach Is Required


Aecon Group Inc. (ARE:CA) Q4 2025 Earnings Call Transcript

Mar 6, 2026, 2:55 PM EST - 27 days ago

Aecon Group Inc. (ARE:CA) Q4 2025 Earnings Call Transcript


Seven S&P500 Ideal 'Safer' March Dividend Dogs

Mar 4, 2026, 11:31 AM EST - 4 weeks ago

Seven S&P500 Ideal 'Safer' March Dividend Dogs

AMCR BBY BEN BXP CAG CCI CPB


Private Credit Default Rates Could Hit 15%, UBS Warns

Feb 25, 2026, 10:59 AM EST - 5 weeks ago

Private Credit Default Rates Could Hit 15%, UBS Warns

ARES BX OWL


Alexandria Real Estate Q4 Results: The Good, The Bad, The Ugly

Feb 10, 2026, 7:50 AM EST - 7 weeks ago

Alexandria Real Estate Q4 Results: The Good, The Bad, The Ugly


1 Popular REIT To Sell And 1 Hated REIT To Buy

Jan 27, 2026, 8:50 AM EST - 2 months ago

1 Popular REIT To Sell And 1 Hated REIT To Buy

VNQ WELL


Here's How Not To Invest $100,000 In 2026

Jan 21, 2026, 12:08 PM EST - 2 months ago

Here's How Not To Invest $100,000 In 2026

BTI CAG DOW ECC IBM NEE SCHD


Powell Under Pressure

Jan 19, 2026, 9:00 AM EST - 2 months ago

Powell Under Pressure

AGG AGNC AGNCM AGNCN AGNCO AGNCP AHT


Hopipaytrader
Hopipaytrader Apr. 2 at 8:34 PM
$ARE rate cuts, move to risk on in biotech already started, expect filled lab spaces, good outlook
0 · Reply
StockFactz
StockFactz Apr. 2 at 7:20 PM
$ARE An overcriticized move is also that people dislike ARE creating rent concessions for the short term to entice new leasees or to encourage renewals. If they are able to fill in space with rent concessions that is infinitely better for the company than the current bear projections. Q4 2025 was actually a huge leasing quarter for them, it was double that of the last 5 quarters. For example right now the stock is priced as if the occupancy rate will drop to 3% this year. If they can backfill the space or encourage renewals with a 20% discount then the company is actually only losing 0.6%. This is a short term strategy that will help the company while the market adjusts and gives time for tenants to rotate back in with biotech cycle. The bear thesis is that this is indicative of a long term spiral and bleed out period, but it seems to be this is an obvious and responsible play by the company to open up their options and increase cash flow https://www.costar.com/article/431378465/alexandrias-leasing-jump-signals-potential-rebound-in-biotech-property-demand
0 · Reply
StockFactz
StockFactz Apr. 2 at 7:05 PM
$ARE The current price levels only make sense if the reality is continued bleed out or drop in tenancy across the next 5-10 years and occupancy dips to like 60%. Which doesn't really seem to be rooted in any factuality. It seems to me like theres a fairly decent chance things will turn bullish or even remain neutral at the very least. BIG HYPOTHETICAL, but if occupancy recovers to 95% in the next 2 years (which is just a 6% or so gain), then the consensus is that this stock is worth double or triple. I haven't seen any compelling evidence that the bearish case is any more likely than a bullish or neutral case. In fact I would estimate that a dip to 60% tenancy is practically less than 5%. A lighter bear case of 80% tenancy is maybe 15%. Neutral case is 45%, bullish case is 35%.
1 · Reply
StockFactz
StockFactz Apr. 2 at 6:44 PM
$ARE Nice little snippet!!! Quality innovation centers are always going to be needed, and perhaps even more so in the coming years. The current narrative that AI will reduce the need for lab space seems completely backwards. Buy and hold for 5 years! This will be at $200 levels and the dividend will be 2-4X.
0 · Reply
weko
weko Apr. 2 at 1:01 PM
$ARE Just saw 45% dividend cut
1 · Reply
weko
weko Apr. 2 at 12:05 PM
$ARE The trend line on the monthly chart hits at long term 2010-2014 support around 39-40. I will buy back in if it hits there with a dividend near 10 pc
2 · Reply
Daniel3303
Daniel3303 Apr. 2 at 11:57 AM
$ARE https://www.cushmanwakefield.com/en/insights/life-science-report
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 10:53 PM
$ARE The market hates logical analysis but I’m gonna provide some anyways. First off it’s no secret that different REITs will a command significantly different valuations and it is often difficult to compare two directly. However let’s work with a key assumption that $BXP AND $ARE both have some key similarities. Namely 1. They both provide premium office real estate in premium US hubs. (ARE does only lab space) 2. They are both industry leaders 3. They are both facing potential headwinds from occupancy and supply Now let’s consider the indisputable facts that $ARE has significantly stickier tenants and a much stronger moat in its respective industry. Let’s also consider that $ARE’s occupancy rate is currently 4% higher, and their debt to equity ratio is extremely trim compared to BXPs high leverage and weaker cash position. Lets also consider that lab space is a lot more “necessary” than traditional office space in the sense that wet labs are in person research is a requirement
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 10:13 PM
$ARE scratch that, the P/FFO is actually 6.7X after today. If it doubled in price it would be at the low end of its historical average of around 14X. Occupancy is at 90%, a majority of the biggest blue chip leases don’t expire dor 7+ years.
0 · Reply
Arb_raccoon
Arb_raccoon Apr. 1 at 8:55 PM
$ARE Entering here - see you boys at $200
0 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 8:26 PM
$ARE bro the P/FFO is literally at like 7X that’s the same as some mall REITs were before they went bankrupt. The current occupancy rate is 90% after a five-year biotech bear market that will likely as soon recover 😭😭
1 · Reply
ThomasTrainTrader
ThomasTrainTrader Apr. 1 at 7:47 PM
$ARE Adjusted for inflation this is way below all time lows, in fact anything below $50 is basically priced at all time lows. While the company is in a position that is far stronger than 75% of its lifespan
2 · Reply
StockFactz
StockFactz Apr. 1 at 7:40 PM
$ARE High-quality lab space in core innovation hubs will always be valuable, and profitable
1 · Reply
StockFactz
StockFactz Apr. 1 at 7:34 PM
$ARE - "The price fell because the dividend fell" No actually the dividend is higher than it was in 2013 and similar to 2015 where it was trading at double the price. - "The stock has P/FFO ratio that is too high and needs to be adjusted for market headwinds" Well no, actually it is trading at historic lows, close to 1/3 of previous highs and 1/2 of previous lows. The P/FFO is so low it's essentially being priced like a 50 year old decaying office building in Detroit when the real estate they own sits in the most luxurious and high end business/health centers in the world, and has proven high demand even with market headwinds.
0 · Reply
Arcides
Arcides Apr. 1 at 7:27 PM
$ARE will this garbage go to the 2009 low (30.33)?
1 · Reply
Koapark
Koapark Apr. 1 at 7:26 PM
$ARE Impressive sell off to say the least. For no particular reason. I’ve always had 35 as a target, not because I think that’s how the company should be valued but because the market almost always overshoots upside and downside. It’s a screaming buy now. Will be even more insane buy in the 30s - I’ll be loading my bag bigly
0 · Reply
StockFactz
StockFactz Apr. 1 at 7:12 PM
$ARE THIS IS GENERATIONAL FREE MONEY!!!!! When it hits $65 in a couple months I will make a clean $40K plus all the dividends
0 · Reply
JPEstrada
JPEstrada Apr. 1 at 7:11 PM
$ARE the one and 5 year charts on this piece of shit look terrible. Just bleeding. Sitting out for further crashing.
1 · Reply
StockFactz
StockFactz Apr. 1 at 7:09 PM
$ARE Don't freak out longs, enjoy the free money
1 · Reply
StockFactz
StockFactz Apr. 1 at 7:02 PM
$ARE Picked up another $15K will hold like $30K in reserve hopefully I dont regret not jumping on the buy opportunity with more
0 · Reply
StockFactz
StockFactz Apr. 1 at 7:00 PM
$ARE Lowkey considering using $40-50K of margin on this right now....... this is how insane I feel like the price is right now. I've never seen anything like this for a REIT or similar genres of equity
1 · Reply
StockFactz
StockFactz Apr. 1 at 6:51 PM
$ARE -6% for no reason (-54% last 1Y) while market rips up including biotech, this is completely unreasonable, I always buy divergence from common sense
1 · Reply